Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 2Phase 1 2

Status

Completed 4

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 102Sarcoma 16Thoracic 6Gynecologic 5CNS 5Genitourinary 4Dermatologic 4Tumor-Agnostic 3Other solid neoplasm 2Head & Neck 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 2Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer) 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

Docetaxel 191Gemcitabine 148Prednisone 142pembrolizumab 125enzalutamide 119Abiraterone Acetate 108Nivolumab 107Cisplatin 103Magnetic Resonance Spectroscopy 100Radiotherapy 95Sunitinib 94Leuprolide 91Carboplatin 82Specimen Handling 71Androgen Antagonists 63bicalutamide 60Radiosurgery 60Paclitaxel 59Goserelin 59Ipilimumab 57Bevacizumab 57apalutamide 53Sorafenib 53acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 51Everolimus 49cabozantinib 48abiraterone 46atezolizumab 45cabazitaxel 43durvalumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 2 × regorafenib × Genitourinary × Clear all
NCT03890731 2024-04-02

A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed

Bayer

Phase 2 Completed
6 enrolled 11 charts
GastrointestinalGenitourinary

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Colorectal Neoplasms

NCT02795156 2023-12-05

Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations

SCRI Development Innovations, LLC

Phase 2 Completed
100 enrolled 14 charts
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell

NCT00664326 2021-01-29

A Phase II Uncontrolled Study of BAY73-4506 in Previously Untreated Patients With Metastatic or Unresectable RCC

Bayer

Phase 2 Completed
49 enrolled 20 charts
Genitourinary

Carcinoma, Renal Cell

NCT02459119 2020-08-06

Study of Regorafenib for Urothelial Cancer Following Chemotherapy (UAB 1477)

University of Alabama at Birmingham

Phase 2 Completed
17 enrolled 11 charts
Genitourinary

Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡